{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:52:49Z","timestamp":1791204769321,"version":"4.2.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["JQ24041"],"award-info":[{"award-number":["JQ24041"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of China","doi-asserted-by":"publisher","award":["JYB2025XDXM603"],"award-info":[{"award-number":["JYB2025XDXM603"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endovascular therapy is the standard of care for eligible patients with acute ischemic stroke due to LVO. However, nearly half of patients remain functionally dependent even after successful reperfusion. Albumin is a biologically plausible adjunctive cerebroprotective therapy and has shown neuroprotective effects in preclinical studies, but the clinical benefit of albumin combined with EVT remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2) is an investigator-initiated, prospective, multicenter, randomised, open-label, controlled trial with blinded endpoint assessment (PROBE design). Eligible participants will be randomly assigned in a 1:1 ratio to receive either EVT plus intravenous 25% albumin at 0.5\u00a0g\/kg (maximum dose, 37.5\u00a0g) initiated within 60\u00a0min after randomisation and then repeated once daily on days 2\u20134, or EVT alone. The initial target sample size is 1192 participants (596 per group). A prespecified adaptive sample size re-estimation will be performed after approximately 50% of participants have completed the 90-day follow-up, allowing the total sample size to be increased, but not reduced, to a maximum of 1788 participants. This trial aims to evaluate the efficacy and safety of albumin administered in combination with EVT in patients with acute ischemic stroke caused by anterior circulation LVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study endpoints<\/jats:title>\n                    <jats:p>The primary outcome is a favourable functional outcome at 90\u00a0days, defined as a mRS score of 0\u20132, or return to the premorbid mRS for participants with a prestroke mRS score of 3\u20134.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The ARISE-2 trial is designed to evaluate the efficacy and safety of moderate-dose albumin combined with EVT in participants with acute ischemic stroke caused by anterior circulation LVO. The trial will provide evidence on whether albumin can improve functional outcomes as an adjunctive cerebroprotective strategy in patients undergoing reperfusion therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT07263308.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/esj\/aakag119","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:11:08Z","timestamp":1791202268000},"source":"Crossref","is-referenced-by-count":0,"title":["Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0541-5286","authenticated-orcid":false,"given":"Zilin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9209-0681","authenticated-orcid":false,"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1800-8744","authenticated-orcid":false,"given":"Yanbo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, People's Hospital of Huazhou , Maoming ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8083-3575","authenticated-orcid":false,"given":"Yuzhang","family":"Bei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liuyang Jili Hospital , Liuyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-5586","authenticated-orcid":false,"given":"Yong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liuyang Jili Hospital , Liuyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1382-9780","authenticated-orcid":false,"given":"Yanling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shenqiu County People's Hospital , Zhoukou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-5899","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Linyi City People Hospital , Linyi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5516-9888","authenticated-orcid":false,"given":"Lingling","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongmu County People's Hospital , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1541-404X","authenticated-orcid":false,"given":"Le","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3736-9510","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0327-0625","authenticated-orcid":false,"given":"Yuhang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-6978","authenticated-orcid":false,"given":"Lan","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Brain Disorders, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1734","authenticated-orcid":false,"given":"Jinyue","family":"Li","sequence":"additional","affiliation":[{"name":"National Stroke Administration Office, Xuanwu Hospital Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-2852","authenticated-orcid":false,"given":"Xunming","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]},{"name":"Beijing Institute of Brain Disorders, Capital Medical University , Beijing ,","place":["China"]},{"name":"Institute of Clinical Research, Chinese Academy of Medical Sciences\/Peking Union Medical College , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-416X","authenticated-orcid":false,"given":"Chuanjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University , Beijing ,","place":["China"]},{"name":"Beijing Institute of Brain Disorders, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100508110303500_ref1","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1161\/STR.0000000000000513","article-title":"Guideline for the early Management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"57","author":"Prabhakaran","year":"2026","journal-title":"Stroke."},{"key":"2026100508110303500_ref2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1056\/NEJMoa1713973","article-title":"Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging","volume":"378","author":"Albers","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100508110303500_ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100508110303500_ref4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"2026100508110303500_ref5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1515\/rns.2011.028","article-title":"Current perspectives on potential role of albumin in neuroprotection","volume":"22","author":"Prajapati","year":"2011","journal-title":"Rev Neurosci"},{"key":"2026100508110303500_ref6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/01.str.32.2.553","article-title":"Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window","volume":"32","author":"Belayev","year":"2001","journal-title":"Stroke."},{"key":"2026100508110303500_ref7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1161\/hs0402.105555","article-title":"Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses","volume":"33","author":"Belayev","year":"2002","journal-title":"Stroke."},{"key":"2026100508110303500_ref8","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1161\/01.Str.0000231388.72646.05","article-title":"The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: physiological responses and safety results","volume":"37","author":"Ginsberg","year":"2006","journal-title":"Stroke."},{"key":"2026100508110303500_ref9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1161\/01.STR.0000231389.34701.b5","article-title":"The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis","volume":"37","author":"Palesch","year":"2006","journal-title":"Stroke."},{"key":"2026100508110303500_ref10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/strokeaha.110.596072","article-title":"The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2","volume":"42","author":"Ginsberg","year":"2011","journal-title":"Stroke."},{"key":"2026100508110303500_ref11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/strokeaha.110.610980","article-title":"The albumin in acute stroke part 1 trial: an exploratory efficacy analysis","volume":"42","author":"Hill","year":"2011","journal-title":"Stroke."},{"key":"2026100508110303500_ref12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s1474-4422(13)70223-0","article-title":"High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial","volume":"12","author":"Ginsberg","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026100508110303500_ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131390","article-title":"Albumin Administration in Acute Ischemic Stroke: safety analysis of the ALIAS part 2 multicenter trial","volume":"10","author":"Hill","year":"2015","journal-title":"PLoS One"},{"key":"2026100508110303500_ref14","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/strokeaha.116.012825","article-title":"ALIAS (albumin in acute ischemic stroke) trials: analysis of the combined data from parts 1 and 2","volume":"47","author":"Martin","year":"2016","journal-title":"Stroke."},{"key":"2026100508110303500_ref15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41467-026-72270-6","article-title":"Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial","volume":"17","author":"Liu","year":"2026","journal-title":"Nat Commun"},{"key":"2026100508110303500_ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"Bmj."},{"key":"2026100508110303500_ref17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3760\/cma.j.cn113694-20240410-00221","article-title":"Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2023","volume":"57","author":"CMABo","year":"2024","journal-title":"Chin J Neurol"},{"key":"2026100508110303500_ref18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3760\/cma.j.cn113694-20220714-00548","article-title":"Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022","volume":"55","author":"Chinese","year":"2022","journal-title":"Chin J Neurol"},{"key":"2026100508110303500_ref19","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/sim.4102","article-title":"Adaptive increase in sample size when interim results are promising: a practical guide with examples","volume":"30","author":"Mehta","year":"2011","journal-title":"Stat Med"},{"key":"2026100508110303500_ref20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/strokeaha.125.052147","article-title":"Updated priorities for cerebroprotection trials","volume":"57","author":"Savitz","year":"2026","journal-title":"Stroke."},{"key":"2026100508110303500_ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-086850","article-title":"Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial","volume":"392","author":"Wang","year":"2026","journal-title":"Bmj."},{"key":"2026100508110303500_ref22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaneurol.2023.1871","article-title":"Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial","volume":"80","author":"Wang","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026100508110303500_ref23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaneurol.2023.1660","article-title":"Safety and efficacy of ApTOLL in patients with ischemic stroke undergoing endovascular treatment: a phase 1\/2 randomized clinical trial","volume":"80","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026100508110303500_ref24","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1136\/jnis-2025-023998","article-title":"Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial","volume":"18","author":"Du","year":"2025","journal-title":"J Neurointerv Surg"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/10\/aakag119\/71601555\/aakag119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/10\/aakag119\/71601555\/aakag119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:11:17Z","timestamp":1791202277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/doi\/10.1093\/esj\/aakag119\/8864863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/esj\/aakag119","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"aakag119"}}